NBE-Therapeutics today closed the extension of its seed funding round, led by the Boehringer Ingelheim Venture Fund and additional private investors. The seed funding in aggregate provides CHF 2.1 mio (€ 1.7 mio) working capital to NBE-Therapeutics. In addition with the closing of the seed financing round, the company has been converted from a limited liability company (LLC, or GmbH) into a Swiss AG (Ltd.). The seed funds are intended to further develop and to leverage NBE-Therapeutics' proprietary antibody discovery and enzymatic payload conjugation technologies for the development of so-called "next-generation" antibody drug conjugates (ADCs) for the better therapy of cancer.